Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).

Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).

Abstract: Scales are prevented or inhibited from forming in a well or in a formation penetrated by a well by pumping into the well a fluid comprising a hydratable polymer, a crosslinking agent, such as an organometallic crosslinking agent containing a polyvalent metal and a scale inhibitor selected from the group consisting of polyvinyl sulfonates, a polyacrylamidomethylpropane sulfonic acid, carboxymethyl inulin and sulfonated polyacrylates and mixtures thereof.

Abstract: Scales are prevented or inhibited from forming in a well or in a formation penetrated by a well by pumping into the well a fluid comprising a hydratable polymer, a crosslinking agent, such as an organometallic crosslinking agent containing a polyvalent metal and a scale inhibitor selected from the group consisting of polyvinyl sulfonates, a polyacrylamidomethylpropane sulfonic acid, carboxymethyl inulin and sulfonated polyacrylates and mixtures thereof.

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.

Abstract: Scales are prevented or inhibited from forming in a well or in a formation penetrated by a well by pumping into the well a fluid comprising a hydratable polymer, a crosslinking agent, such as an organometallic crosslinking agent containing a polyvalent metal and a scale inhibitor selected from the group consisting of polyvinyl sulfonates, a polyacrylamidomethylpropane sulfonic acid, carboxymethyl inulin and sulfonated polyacrylates and mixtures thereof.

Abstract: Polymers are derivatized and then may be introduced into a wellbore, such as in a hydraulic fracturing treatment. A polymer may be a guar powder that is mixed with a organic solvent and derivatized using a derivatizing agent, such as sodium chloroacetate. The polymer is typically derivatized in bulk prior to introduction into the wellbore. The derivatized polymer may be hydrated and/or crosslinked prior to introduction into the wellbore.

Abstract: Compositions and methods for modifying the permeability of subterranean formations for the purpose of selectively reducing excessive production of aqueous fluids. The compositions include copolymers which may be added to an aqueous fluid to form a water control treatment fluid. The copolymers may include copolymers having a hydrophillic monomeric unit, a first anchoring monomeric unit and a filler monomeric unit, with the first anchoring monomeric unit being based on N-vinylformamide. Additional anchoring monomeric units may also optionally be present. The copolymers may be employed in well treatment fluids introduced into production wells or injection wells. The copolymers may also be utilized in conjunction with stimulation treatments and with introduction of other well treatment fluids.